Urgent.News

What's breaking now, across thousands of outlets.

Business

Hostile threat warning startup Osavul raises €8.5M

A startup launched in light of Russia’s invasion of Ukrainewhose tech helps NATO and governments detect hostile threats before theyescalate has raised €8.5m in a Series A funding round, it said today....

Hostile threat warning startup Osavul raises €8.5M

Osavul, a startup founded amid Russia's invasion of Ukraine, has successfully secured €8.5 million in Series A funding. The European cybersecurity investor, 33N Ventures, led the round, with Balnord, G+D Ventures, and previous investor 42CAP also participating. The total funding raised by Osavul stands at approximately €12 million.

Osavul's AI platform specializes in detecting both cyber and physical threats before they occur. The technology is utilized by NATO, defense, and government entities to scan vast amounts of online and open-source data to pinpoint disinformation campaigns, hostile actions, and cyber threats. The company was co-founded by Ukrainian entrepreneurs Dmytro Plieshakov and Dmytro Bilash, and its development was spurred by the ongoing conflict in Ukraine.

The newly acquired funds will be directed towards expanding Osavul's enterprise client base and broadening its scope in government and defense sectors. Dmytro Plieshakov, Osavul's co-founder and CEO, emphasized the increasing threat to various industries, stating that hybrid attacks now pose a challenge to companies in energy, airports, ports, transport, and finance.

He added that Osavul aims to bridge this gap by providing AI-driven intelligence to businesses worldwide, particularly in regions plagued by conflict and instability. Dmytro Bilash, Osavul's co-founder and chief business development officer, highlighted the company's development under real-world conditions and its ability to serve customers globally, with a growing presence in conflict-ridden areas.

Written by urgent.news from Tech.eu's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at tech.eu →

More in Business

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization…

  • Samsung Bioepis and Teva form strategic partnership for biosimilar development.
  • Two candidates, SB41 and SB44, confirmed to be developed.
  • Teva handles global commercialization, Samsung manages development and manufacturing.

More from Thursday 1 October →